Adaptive Biotechnologies Corp — Director's Dealing 2020

Jun 26, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-06-23

Reporting Person: ROBINS HARLAN S (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-23	Common Stock	M	11100	$6.32	Acquired	11779	Direct
2020-06-23	Common Stock	S	1500	$46.21	Disposed	10279	Direct
2020-06-23	Common Stock	S	9600	$46.95	Disposed	679	Direct
2020-06-24	Common Stock	M	11100	$6.32	Acquired	11779	Direct
2020-06-24	Common Stock	S	8277	$45.72	Disposed	3502	Direct
2020-06-24	Common Stock	S	2823	$46.38	Disposed	679	Direct
2020-06-25	Common Stock	M	11100	$6.32	Acquired	11779	Direct
2020-06-25	Common Stock	S	700	$45.36	Disposed	11079	Direct
2020-06-25	Common Stock	S	6657	$46.84	Disposed	4422	Direct
2020-06-25	Common Stock	S	3743	$47.25	Disposed	679	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-23	Stock Option (Right to Buy)	$6.32	M	11100	Disposed	2025-06-09	Common Stock (11100)	Direct
2020-06-24	Stock Option (Right to Buy)	$6.32	M	11100	Disposed	2025-06-09	Common Stock (11100)	Direct
2020-06-25	Stock Option (Right to Buy)	$6.32	M	11100	Disposed	2025-06-09	Common Stock (11100)	Direct

Footnotes

F1: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.78 to 46.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.46 to 47.36, inclusive.

F4: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.14 to 45.99, inclusive.

F5: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.00 to 46.93, inclusive.

F6: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.11 to 46.05, inclusive.

F7: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.11 to 47.10, inclusive.

F8: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.11 to 47.48, inclusive.

F9: The option is fully vested and exercisable.